Abstract
Increasing global travel and changes in the environment may escalate the frequency of contact with a natural host carrying an infection and, therefore, increase our chances of encountering microorganisms previously unknown to humans. During an emergency, the etiology of infection may be unknown at the time of patient treatment. The existing local or global Antimicrobial Stewardship Programs may not be fully prepared for emerging/re-emerging infectious disease outbreaks, especially if they are caused by an unknown organism, engineered bioterrorist attack, or rapidly evolving superbug. We demonstrate an antimicrobial efficacy profiling method that can be performed in hours directly from clinical urine specimens. The antimicrobial potency was determined by the level of microbial growth inhibition and compared to conventional antimicrobial susceptibility testing results. The oligonucleotide probe pairs on the sensors were designed to target Gram-negative bacteria, specifically Enterobacterales and Pseudomonas aeruginosa. A pilot study of 10 remnant clinical specimens from the Clinical Laboratory Improvement Amendments-certified labs of New York-Presbyterian Queens was conducted, and only one sample was not detected by the probes. The remaining nine samples agreed with reference AST methods (Vitek and broth microdilution), resulting in 100% categorical agreement. In a separate feasibility study, we evaluated a dual-kinetic response approach, in which we inoculated two antibiotic stripwells containing the same antimicrobial concentrations with clinical specimens at the original concentration (1x) and at a 10-fold dilution (0.1x) to cover a broader range of microbiological responses. The combined categorical susceptibility reporting of 12 contrived urine specimens was 100% for ciprofloxacin, gentamicin, and meropenem over a range of microbial loads from 105 to 108 CFU/mL.
Funder
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Allergy and Infectious Diseases
Publisher
Public Library of Science (PLoS)
Reference66 articles.
1. The Slow March toward Rapid Phenotypic Antimicrobial Susceptibility Testing: Are We There Yet?;CD Doern;J Clin Microbiol,2018
2. Antibiotic treatment for COVID-19 complications could fuel resistant bacteria;S. Reardon;Science,2020
3. Clinical and epidemiological characteristics of pediatric SARS-CoV-2 infections in China: A multicenter case series.;C Zhang;PLoS Med,2020
4. AFP in Geneva. WHO warns overuse of antibiotics for Covid-19 will cause more deaths. The Guardian. 2020 Jun 1 [Cited 2021 Jan 12]. Available from: https://www.theguardian.com/world/2020/jun/01/who-warns-overuse-of-antibiotics-for-covid-19-will-cause-more-deaths.
5. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study;F Zhou;Lancet,2020
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献